JP2009514874A5 - - Google Patents

Download PDF

Info

Publication number
JP2009514874A5
JP2009514874A5 JP2008539056A JP2008539056A JP2009514874A5 JP 2009514874 A5 JP2009514874 A5 JP 2009514874A5 JP 2008539056 A JP2008539056 A JP 2008539056A JP 2008539056 A JP2008539056 A JP 2008539056A JP 2009514874 A5 JP2009514874 A5 JP 2009514874A5
Authority
JP
Japan
Prior art keywords
administered
effective amount
therapeutically effective
medicament
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008539056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009514874A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/042950 external-priority patent/WO2007056135A1/en
Publication of JP2009514874A publication Critical patent/JP2009514874A/ja
Publication of JP2009514874A5 publication Critical patent/JP2009514874A5/ja
Pending legal-status Critical Current

Links

JP2008539056A 2005-11-04 2006-11-03 Saha及びペメトレキセドを用いて癌を治療する方法 Pending JP2009514874A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73395105P 2005-11-04 2005-11-04
PCT/US2006/042950 WO2007056135A1 (en) 2005-11-04 2006-11-03 Method of treating cancers with saha and pemetrexed

Publications (2)

Publication Number Publication Date
JP2009514874A JP2009514874A (ja) 2009-04-09
JP2009514874A5 true JP2009514874A5 (enExample) 2009-12-17

Family

ID=38023582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008539097A Pending JP2009514889A (ja) 2005-11-04 2006-11-03 癌を治療するためにsaha及びボルテゾミブを用いる方法
JP2008539056A Pending JP2009514874A (ja) 2005-11-04 2006-11-03 Saha及びペメトレキセドを用いて癌を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008539097A Pending JP2009514889A (ja) 2005-11-04 2006-11-03 癌を治療するためにsaha及びボルテゾミブを用いる方法

Country Status (7)

Country Link
US (4) US20070117815A1 (enExample)
EP (2) EP1954284A4 (enExample)
JP (2) JP2009514889A (enExample)
CN (3) CN101325955A (enExample)
AU (2) AU2006311808A1 (enExample)
CA (2) CA2636596A1 (enExample)
WO (2) WO2007056232A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2394022C2 (ru) * 2002-03-04 2010-07-10 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС Способы индукции конечной дифференцировки
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2005070020A2 (en) * 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
AU2005249492B2 (en) 2004-05-27 2011-09-22 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
EP2302053A1 (en) 2004-11-12 2011-03-30 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
MX2007011148A (es) * 2005-03-11 2008-02-22 Univ Colorado Inhibidores de histona desacetilasa que sensibilizan celulas cancerosas respecto a los inhibidores de factor de crecimiento.
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme 1,8-辛二醯基苯胺羥胺酸(suberoylanilide hydroxamic acid)之調配物及其製配方法
WO2007056244A2 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer
CA2636596A1 (en) * 2005-11-04 2007-05-18 James Pluda Method of treating cancers with saha and pemetrexed
AU2006313517B2 (en) 2005-11-10 2013-06-27 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
CA2661024A1 (en) * 2006-08-28 2008-03-06 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
WO2008057456A2 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
CA2669675A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
GB2454118B (en) * 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20100298270A1 (en) * 2007-07-23 2010-11-25 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009064300A1 (en) * 2007-11-15 2009-05-22 The Johns Hopkins University Combinations of hdac inhibitors and cytokines/growth factors
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CA2710377A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
ES2610130T3 (es) 2007-12-27 2017-04-26 Infinity Pharmaceuticals, Inc. Métodos para reducción estereoselectiva
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CN102099025A (zh) * 2008-05-16 2011-06-15 马尔药品公司 Pm00104与另一抗肿瘤剂的联合疗法
EP2462115B1 (en) 2009-08-05 2016-01-06 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
KR20120053052A (ko) * 2009-08-25 2012-05-24 아브락시스 바이오사이언스, 엘엘씨 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법
WO2011063309A1 (en) * 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
KR101530942B1 (ko) * 2010-03-18 2015-06-23 이노파르마, 인코포레이티드 안정한 보르테조밉 포뮬레이션
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
EP2547693B1 (en) 2010-03-19 2015-03-11 H. Lee Moffitt Cancer Center & Research Institute Integrin interaction inhibitors for the treatment of cancer
CN104399081A (zh) * 2010-09-01 2015-03-11 诺华有限公司 Hdac抑制剂与血小板减少症药物的组合
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2622076A1 (en) * 2010-09-30 2013-08-07 University of Zürich Treatment of b-cell lymphoma with microrna
CA2862798C (en) 2011-02-17 2021-04-06 The Administrators Of The Tulane Educational Fund Multicomponent compositions and their uses
US20140080762A1 (en) * 2011-03-21 2014-03-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Hyd1 peptides for relapsed cancer
WO2013023043A2 (en) * 2011-08-10 2013-02-14 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
WO2015069693A1 (en) * 2013-11-05 2015-05-14 Dana-Farber Cancer Institute, Inc. Inhibitors of histone deacetylase
CA2988289C (en) 2015-06-04 2023-12-05 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US9746477B2 (en) * 2015-07-30 2017-08-29 Expression Pathology, Inc. Quantifying FR-α and GART proteins for optimal cancer therapy
WO2018195067A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
KR102040034B1 (ko) 2017-12-13 2019-11-05 주식회사 아이큐어비앤피 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법
CN108821999A (zh) * 2018-04-26 2018-11-16 南昌大学 一种氨基酸异羟肟酸类氨肽酶n抑制剂及制备方法
CN113631158A (zh) * 2018-12-10 2021-11-09 转化药物开发有限责任公司 (s)-n-羟基-2-(2-(4-甲氧基苯基)丁酰胺基)噻唑-5-甲酰胺及其药学上可接受的盐
CN116585216A (zh) * 2022-05-16 2023-08-15 上海中翊日化有限公司 一种含有羟基频哪酮视黄酸酯(hpr)并降低光损伤及炎症的抗衰组合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895347A (en) * 1973-09-10 1975-07-15 Bridgestone Tire Co Ltd System for transmitting information of reduced pneumatic pressure of tire
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
CA2383999A1 (en) * 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
AU777047B2 (en) * 2000-02-25 2004-09-30 Eli Lilly And Company A novel crystalline form of N-(4-(2-(2-amino-4,7-dihydro-4- oxo-3H-pyrrolo(2,3-d)pyrimidin-5-YL)ethyl)benzoyl)-L- glutamic acid and process therefor
US20050004007A1 (en) * 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US6501372B2 (en) * 2001-02-02 2002-12-31 Trw Inc. Tire condition sensor communication with unique sampling on vehicle-side diversity antenna array
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2450129A1 (en) * 2001-06-14 2002-12-27 Donald G. Jackson Novel human histone deacetylases
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
RU2394022C2 (ru) * 2002-03-04 2010-07-10 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС Способы индукции конечной дифференцировки
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
JP2005530739A (ja) * 2002-04-19 2005-10-13 セルラー ジェノミクス,インコーポレーテッド イミダゾ[1,2−a]ピラジン−8−イルアミン、生成方法、および使用方法
CN1674917A (zh) * 2002-06-24 2005-09-28 研究发展基金会 用姜黄素治疗人多发性骨髓瘤
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
WO2004053066A2 (en) * 2002-12-06 2004-06-24 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
JP2006523693A (ja) * 2003-04-01 2006-10-19 メモリアル スローン−ケタリング キャンサー センター ヒドロキサム酸化合物およびその使用方法
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
PL2238982T3 (pl) * 2003-06-27 2013-03-29 Astellas Pharma Inc Środek do terapii mięsaka tkanek miękkich
SI1663194T1 (sl) * 2003-08-26 2010-08-31 Merck Hdac Res Llc Uporaba SAHA za zdravljenje mezotelioma
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
SG171690A1 (en) * 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
WO2007056244A2 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer
EP1942884A4 (en) * 2005-11-04 2010-01-06 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES
CA2636596A1 (en) * 2005-11-04 2007-05-18 James Pluda Method of treating cancers with saha and pemetrexed
WO2008057456A2 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma

Similar Documents

Publication Publication Date Title
JP2009514874A5 (enExample)
JP2005510535A5 (enExample)
JP2018520189A5 (enExample)
JP2010518122A5 (enExample)
JP2006504795A5 (enExample)
JP2015522630A5 (enExample)
JP2010521417A5 (enExample)
JP2019516684A5 (enExample)
IL273169B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
JP2010065060A (ja) 心不全処置のための複合治療
JP2019218379A5 (enExample)
JP2018531273A5 (enExample)
JP2009517411A5 (enExample)
JP2020523334A5 (enExample)
CN104039148A (zh) 组合als疗法
JP2016505050A5 (enExample)
JP2001515041A5 (enExample)
JP2019507786A5 (enExample)
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP2019531286A5 (enExample)
EP4045058A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
JP2008533022A5 (enExample)
HRP20251043T1 (hr) Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća
JP2013518061A5 (enExample)
JP2021091608A5 (enExample)